Pharmacokinetically stabilized cystine knot peptides that bind Alpha-v-Beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 839-849

  Kimura, Richard H ^a   Teed, Robert ^a   Hackel, Benjamin J ^a   Pysz, Marybeth A ^a   Chuang, Courtney Z ^a   Sathirachinda, Ataya ^a   Willmann, Jürgen K ^a   Gambhir, Sanjiv S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; ARGININE; CYSTINE KNOT SCAFFOLD; DISULFIDE; GLUTAMIC ACID; SERINE; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSS REACTION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; EARLY DIAGNOSIS; FEMALE; INJECTION; KIDNEY CLEARANCE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; URINE RETENTION;

ANIMALS; ANTIGENS, NEOPLASM; BIOENGINEERING; CYSTINE-KNOT MINIPROTEINS; FEMALE; HUMANS; INTEGRINS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84856513069     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1116     Document Type: Article

References (38)

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87. (Pubitemid 35283958)
2. Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets 2009;10:645-52.
3. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995;108:2655-61.
4. Varner JA, Brooks PC, Cheresh DA. REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Cell Adhes Commun 1995; 3:367-74.
5. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002;23:237-44. (Pubitemid 34223999)
6. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004;45:226-36. (Pubitemid 39279179)
7. Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res 2007;67:7833-40. (Pubitemid 47281378)
8. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, et al. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 2009;69:5843-50.
9. Hausner SH, Kukis DL, Gagnon MK, Stanecki CE, Ferdani R, Marshall JF, et al. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6- specific peptide. Mol Imaging 2009;8:111-21.
10. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007;212:316-24. (Pubitemid 47010065)
11. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-47. (Pubitemid 40385475)
12. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007; 67:5889-95. (Pubitemid 46985024)
13. Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982;298:30-3. (Pubitemid 12087468)
14. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999;274:1979-85.
15. Hsiao JR, Chang Y, Chen YL, Hsieh SH, Hsu KF, Wand CF, et al. Cyclic alphavbeta6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma. Head Neck 2010;32:160-72.
16. Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Kramer S, Herold- Mende C, Altmann A, et al. Identification and characterization of a peptide with affinity to head and neck cancer. J Nucl Med 2009;50: 426-34.
17. Gagnon MK, Hausner SH, Marik J, Abbey CK, Marshall JF, Sutcliffe JL. High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A 2009;106:17904-9.
18. Tangri S, LiCalsi C, Sidney J, Sette A. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem 2002;9:2191-9. (Pubitemid 35364011)
19. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009;69:2435-42.
20. Miao Z, Ren G, Liu H, Kimura RH, Jiang L, Cochran JR, et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 2009;20:2342-7.
21. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010;51:433-40.
22. Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 2009;77:359-69.
23. Colgrave ML, Craik DJ. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 2004;43:5965-75. (Pubitemid 38669464)
24. Gran L. Oxytocic principles of Oldenlandia affinis. Lloydia 1973; 36:174-8.
25. Gran L, Sletten K, Skjeldal L. Cyclic peptides from Oldenlandia affinis DC. Molecular and biological properties. Chem Biodivers 2008; 5:2014-22.
26. Swers JS, Kellogg BA, Wittrup KD. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res 2004;32:e36.
27. Lipovsek D, Lippow SM, Hackel BJ, Gregson MW, Cheng P, Kapila A, et al. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 2007;368:1024-41. (Pubitemid 46584683)
28. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Culabeled tetrameric RGD peptide. J Nucl Med 2005;46:1707-18. (Pubitemid 46211595)
29. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, et al. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti- related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med 2010;51:251-8.
30. Heitz A, Hernandez JF, Gagnon J, Hong TT, Pham TT, Nguyen TM, et al. Solution structure of the squash trypsin inhibitor MCoTI-II. A new family for cyclic knottins. Biochemistry 2001;40:7973-83. (Pubitemid 32641194)
31. Cemazar M, Joshi A, Daly NL, Mark AE, Craik DJ. The structure of a two-disulfide intermediate assists in elucidating the oxidative folding pathway of a cyclic cystine knot protein. Structure 2008;16:842-51. (Pubitemid 351778379)
32. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17. (Pubitemid 28532555)
33. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010;37:1356-67.
34. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem 2010;21: 947-54.
35. Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613-22.
36. Hansson M, Ringdahl J, Robert A, Power U, Goetsch L, Nguyen TN, et al. An in vitro selected binding protein (affibody) shows conformation- dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 1999;4:237-52. (Pubitemid 29170032)
37. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Milsson FY, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 2007;20:189-99. (Pubitemid 351321300)
38. Hogbom M, Eklund M, Nygren PA, Nordlund P. Structural basis for recognition by an in vitro evolved affibody. Proc Natl Acad Sci U S A 2003;100:3191-6. (Pubitemid 36358201)